[Alltek] Announcement of Shareholder Meeting Resolution to Release Directors and Representatives from Non-Compete Obligations
Alltek held its annual general meeting on May 20, 2026, approving the release of non-compete obligations for its directors and their representatives. The approval covers Qisda Corporation, its representatives, and independent directors. The move has no impact on financials.
📋 Article Processing Timeline
- 📰 Published: May 20, 2026 at 09:00
- 🔍 Collected: May 21, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 21, 2026 at 08:00 (0 min after Collected)
1. Date of shareholder meeting resolution: May 20, 2026
2. Names and titles of directors permitted to engage in competitive behavior:
(1) Corporate Director: Qisda Corporation
(2) Corporate Director: Xue Daolong, Representative of Qisda Corporation
(3) Corporate Director: Hong Qiujin, Representative of Qisda Corporation
(4) Independent Director: Ye Huixin
(5) Independent Director: Zhu Xuanlian
3. Scope of permitted competitive behavior:
(1) Qisda Corporation: Chairman of Qisda Vietnam Corporation, Director of GeneReach Biotechnology, Chairman of DFI, Director of AUO, etc.
(2) Xue Daolong: Chairman of Qisda Electronic, Director of Etron Technology, etc.
(3) Hong Qiujin: Representative of Shanghai Felte Technology, Representative of BenQ (Nanjing) Hospital, etc.
4. Duration of permission: During the tenure of their position as Alltek directors or their representatives.
5. Resolution status: Approved by two-thirds or more of the voting rights present, representing more than half of the total issued shares.
6. Directors involved in Mainland China operations: Hong Qiujin, representative of Qisda Corporation.
7. Mainland China entities and roles: Representative for Shanghai Felte Technology, Nanjing BenQ Hospital, etc.
8. Locations of Mainland operations: Shanghai, Nanjing, Suzhou.
9. Business scope in Mainland China: Sales of medical equipment, hospital management, R&D in biotechnology.
10. Impact on company's financial and business operations: None.
2. Names and titles of directors permitted to engage in competitive behavior:
(1) Corporate Director: Qisda Corporation
(2) Corporate Director: Xue Daolong, Representative of Qisda Corporation
(3) Corporate Director: Hong Qiujin, Representative of Qisda Corporation
(4) Independent Director: Ye Huixin
(5) Independent Director: Zhu Xuanlian
3. Scope of permitted competitive behavior:
(1) Qisda Corporation: Chairman of Qisda Vietnam Corporation, Director of GeneReach Biotechnology, Chairman of DFI, Director of AUO, etc.
(2) Xue Daolong: Chairman of Qisda Electronic, Director of Etron Technology, etc.
(3) Hong Qiujin: Representative of Shanghai Felte Technology, Representative of BenQ (Nanjing) Hospital, etc.
4. Duration of permission: During the tenure of their position as Alltek directors or their representatives.
5. Resolution status: Approved by two-thirds or more of the voting rights present, representing more than half of the total issued shares.
6. Directors involved in Mainland China operations: Hong Qiujin, representative of Qisda Corporation.
7. Mainland China entities and roles: Representative for Shanghai Felte Technology, Nanjing BenQ Hospital, etc.
8. Locations of Mainland operations: Shanghai, Nanjing, Suzhou.
9. Business scope in Mainland China: Sales of medical equipment, hospital management, R&D in biotechnology.
10. Impact on company's financial and business operations: None.
FAQ
What was the key resolution passed at Alltek's shareholder meeting?
The meeting passed a resolution regarding the release of directors and representatives from non-compete obligations, aimed at compliance and facilitating cross-role management.
Will this resolution affect Alltek's financials?
No, the announcement stated that this decision has no impact on Alltek's financials or operations.
Why is the release of non-compete obligations necessary?
It is necessary to ensure compliance for directors serving in multiple roles across the Qisda group, enabling smoother inter-company cooperation.